Wealth Management: Investment Views

Vaccines and diagnostics

With the COVID-19 pandemic now into its second year, progress with vaccinations and testing raises the hope that lockdowns will lift and economic life will resume. Based on interviews with Bryan Dunn, investor relations officer at the US pharmaceutical company Pfizer, and Dr. Bruno Eschli, investor relations officer at the Swiss pharmaceutical company Roche, we bring you insights from the pharmaceutical industry about the latest vaccine developments and testing options in the fight against COVID-19.



An interview with Pfizer

One of the greatest breakthroughs during the COVID-19 pandemic has been the development of vaccines. US pharma giant Pfizer and German biotechnology company BioNTech were the first to have their vaccine authorized for emergency use in the West. Since the start of vaccination programmes at the end of 2020, many countries across the developed world are seeing considerable traction in those citizens who have received at least one dose of a COVID-19 vaccine. Leading this race is the Pfizer/ BioNTech vaccine (see figure 1). In the following interview with Pfizer, we find out more about the world’s first mass-produced mRNA vaccine.

Read our interview with Pfizer

An interview with Roche

Besides vaccinations, one component in the fight against COVID-19 is the widespread testing of citizens. In respect to diagnostics, Roche is a long-standing position in our portfolios and one of the leading pharmaceutical companies in the world. In summer 2020, we were fortunate to interview Roche (Investment views: A response to COVID-19) on its initial response to COVID-19. With the advent of the vaccine and rapid advances in testing, we bring you an update on how the world of diagnostics is responding to the fight against COVID-19.

Read our interview with Roche


More Information

View more Wealth Insights


Back to top